Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RCUS Stock Forecast 2025-2026
$8.28
Current Price
$876.73M
Market Cap
Buy 11
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RCUS Price Targets
+455.6%
To High Target of $46.00
+214.0%
To Median Target of $26.00
+57.0%
To Low Target of $13.00
RCUS Price Momentum
-7.4%
1 Week Change
+1.2%
1 Month Change
-50.4%
1 Year Change
-44.4%
Year-to-Date Change
-56.4%
From 52W High of $18.98
+27.4%
From 52W Low of $6.50
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Arcus Biosciences (RCUS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RCUS and similar high-potential opportunities.
Latest RCUS Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, RCUS has a bullish consensus with a median price target of $26.00 (ranging from $13.00 to $46.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $8.28, the median forecast implies a 214.0% upside. This outlook is supported by 11 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Alethia Young at Cantor Fitzgerald, projecting a 455.6% upside. Conversely, the most conservative target is provided by Salveen Richter at Goldman Sachs, suggesting a 57.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RCUS Analyst Ratings
11
Buy
2
Hold
0
Sell
RCUS Price Target Range
Low
$13.00
Average
$26.00
High
$46.00
Current: $8.28
Latest RCUS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RCUS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $22.00 |
| May 8, 2025 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $13.00 |
| May 7, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $26.00 |
| Apr 23, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $14.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Upgrade | $24.00 |
| Feb 19, 2025 | B of A Securities | Jason Zemansky | Neutral | Maintains | $17.00 |
| Feb 18, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $25.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Maintains | $18.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $20.00 |
| Oct 25, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $29.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $20.00 |
| Oct 21, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Initiates | $20.00 |
| Oct 8, 2024 | Wells Fargo | Eva Fortea Verdejo | Overweight | Initiates | $29.00 |
| Oct 7, 2024 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $0.00 |
| Oct 3, 2024 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $0.00 |
| Oct 3, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $30.00 |
| Aug 9, 2024 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $0.00 |
| Aug 9, 2024 | Wedbush | Robert Driscoll | Outperform | Reiterates | $30.00 |
| Aug 9, 2024 | B of A Securities | Jason Zemansky | Neutral | Maintains | $23.00 |
| Jul 8, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $25.00 |
Arcus Biosciences Inc. (RCUS) Competitors
The following stocks are similar to Arcus Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RCUS
Arcus Biosciences
mkt cap
876.73M
Arcus Biosciences Inc. (RCUS) Financial Data
Arcus Biosciences Inc. has a market capitalization of $876.73M with a P/E ratio of -2.6x. The company generates $141.00M in trailing twelve-month revenue with a -277.3% profit margin.
Revenue growth is -80.7% quarter-over-quarter, while maintaining an operating margin of -435.7% and return on equity of -63.2%.
Valuation Metrics
Market Cap
$876.73M
Enterprise Value
$-39,271,056
P/E Ratio
-2.6x
PEG Ratio
-1.8x
Price/Sales
6.2x
Growth & Margins
Revenue Growth (YoY)
-80.7%
Gross Margin
N/A
Operating Margin
-435.7%
Net Margin
-277.3%
EPS Growth
-80.7%
Financial Health
Cash/Price Ratio
+113.7%
Current Ratio
5.4x
Debt/Equity
15.3x
ROE
-63.2%
ROA
-22.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Arcus Biosciences Inc. (RCUS) Business Model
About Arcus Biosciences Inc.
What They Do
Develops innovative cancer therapies.
Business Model
The company operates by developing a range of biopharmaceutical products focused on immuno-oncology, utilizing the immune system to combat cancer. It generates revenue through the advancement of its drug pipeline, which includes monoclonal antibodies and small molecules, and by forming strategic partnerships for research and development.
Additional Information
Arcus Biosciences is positioned in a rapidly evolving industry, emphasizing next-generation treatments to enhance efficacy while reducing side effects. Their focus on innovation and diversification of cancer therapies aims to improve patient outcomes and address complex cancer biology, making them a significant player in the biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
627
CEO
Dr. Terry J. Rosen Ph.D.
Country
United States
IPO Year
2018
Website
www.arcusbio.comArcus Biosciences Inc. (RCUS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -11.76% and 14.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Arcus Biosciences granted options for 21,250 shares at $8.53 each to three new employees, as announced by the company's Board of Directors.
Why It Matters
The granting of stock options to new employees can signal confidence in the company's future and may boost employee motivation, impacting overall performance and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Arcus Biosciences will hold its Q1 2025 earnings call on May 6, 2025, at 4:30 PM ET. Key company executives will participate alongside analysts from major financial firms.
Why It Matters
The upcoming earnings call for Arcus Biosciences may reveal financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
6 days ago
Quick Summary
Arcus Biosciences (NYSE: RCUS) reported Q1 2025 financial results and updated its cancer drug pipeline, highlighting an upcoming ASCO presentation on casdatifan for ccRCC.
Why It Matters
Arcus Biosciences' pipeline update and financial results can signal growth potential and innovation in cancer treatment, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Arcus Biosciences reported a quarterly loss of $1.14 per share, exceeding expectations of a $1.02 loss, compared to a loss of $0.05 per share in the same quarter last year.
Why It Matters
Arcus Biosciences' larger-than-expected quarterly loss signals potential financial instability, which could negatively impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Arcus Biosciences granted options for 39,750 shares at $8.11 each to three new employees, reflecting ongoing growth and investment in talent.
Why It Matters
The granting of stock options indicates confidence in the company's future, potentially aligning employee interests with shareholder value and affecting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Arcus Biosciences (NYSE: RCUS) will present safety and efficacy data from the ARC-20 study at the 2025 ASCO Annual Meeting, scheduled for May 30 – June 3, 2025.
Why It Matters
The upcoming presentation of ARC-20 study data at ASCO 2025 could influence investor sentiment and stock performance for Arcus Biosciences, particularly regarding its cancer therapies' potential.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RCUS Stock
What is Arcus Biosciences Inc.'s (RCUS) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Arcus Biosciences Inc. (RCUS) has a median price target of $26.00. The highest price target is $46.00 and the lowest is $13.00.
Is RCUS stock a good investment in 2025?
According to current analyst ratings, RCUS has 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RCUS stock?
Wall Street analysts predict RCUS stock could reach $26.00 in the next 12 months. This represents a 214.0% increase from the current price of $8.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arcus Biosciences Inc.'s business model?
The company operates by developing a range of biopharmaceutical products focused on immuno-oncology, utilizing the immune system to combat cancer. It generates revenue through the advancement of its drug pipeline, which includes monoclonal antibodies and small molecules, and by forming strategic partnerships for research and development.
What is the highest forecasted price for RCUS Arcus Biosciences Inc.?
The highest price target for RCUS is $46.00 from Alethia Young at Cantor Fitzgerald, which represents a 455.6% increase from the current price of $8.28.
What is the lowest forecasted price for RCUS Arcus Biosciences Inc.?
The lowest price target for RCUS is $13.00 from Salveen Richter at Goldman Sachs, which represents a 57.0% increase from the current price of $8.28.
What is the overall RCUS consensus from analysts for Arcus Biosciences Inc.?
The overall analyst consensus for RCUS is bullish. Out of 17 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $26.00.
How accurate are RCUS stock price projections?
Stock price projections, including those for Arcus Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 12:02 PM UTC